Ciprofol EC50 for Inducing Loss of Consciousness in Elderly Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE4

Total Enrollment

150 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-04-02

Study Completion Date

2025-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

ciprofol is a recently introduced novel sedative drug. In comparison to the traditional propofol, ciprofol exhibits a higher affinity for GABA A receptors, approximately 4-5 times that of propofol, and possesses fewer side effects, particularly notable in respiratory depression and injection pain. In the context of general anesthesia induction, recent research has confirmed a 100% success rate in the induction of general anesthesia for elderly patients (65-80 years old) undergoing non-cardiac surgery with a dosage range of 0.2mg/kg-0.4mg/kg ciprofol. However, for elderly patients aged 65 and above, even up to 85 years old, it is currently not entirely clear what dosage should be selected for patients in different age groups. Consequently, we have designed this trial with the aim of exploring the dosage requirements of ciprofol during general anesthesia induction among elderly patients in various age brackets.

Methods: This is a prospective, non-controlled, non-randomized, single-blind study. Elderly patients aged 65 years and older were enrolled in the study with American Society of Anesthesiologists (ASA) physical status I or II undergoing general anesthesia. All patients were divided into five groups according to age, and the corresponding initial dose of ciprofol administered was selected according to the grouping, with subsequent doses of ciprofol determined according to the Dixon up-and-down method. At least seven crossover points were obtained before the conclusion of the study.The primary outcomes were the dose of ciprofol administered at the time of loss of consciousness (mg/Kg) and the plasma concentration of ciprofol.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Ciprofol Titrated Induction in Reducing Post-induction Hypotension in Geriatric Patients

NCT06258967

Post Induction Hypotension Elderly

RECRUITING NA

Effects of Ciprofol on Postoperative Delirium and Outcomes in Elderly Patients Undergoing Major Thoracic Surgery

NCT06674226

Postoperative Delirium (POD)

RECRUITING PHASE4

The Study of Ciprofol for the Suppression of Cardiovascular Responses to Tracheal Intubation

NCT06095570

Intubation, Intratracheal Adverse Effects

UNKNOWN PHASE4

Safety and Effectiveness of Ciprofol in Cardiac Surgery Anesthesia

NCT05892471

Anesthesia

UNKNOWN NA

Clinical Observation of Ciprofol for Anesthesia Induction

NCT05706337

Anesthesia Pain Hemodynamic Instability

UNKNOWN PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

After received the approvement of ethics committee of the Cancer Hospital of the University of Chinese Academy of Sciences (approval number IRB-2024-76(IIT)). The study was registered before patient enrollment in Clinicaltrials.Written informed consent was obtained from all participants. The study was performed from Jan 1, 2024 to Dec 31, 2025. 150 patients aged 65 years and above, ASA physical status I or II, undergoing surgery under general anesthesia and who were not allergic to the study drug were included in this study. Basic monitoring such as 3-lead electrocardiogram, pulse oximetry, and noninvasive blood pressure were arranged preoperatively. All patients were divided into five groups according to age, The initial dose of ciprofol for the first elderly patient was 0.2-0.4 mg/kg, the initial concentration was 0.4 mg/Kg for patients aged 65-74 years, 0.3 mg/Kg for patients aged 75-84 years, and 0.2 mg/Kg for patients aged 85 years or older, and the ciprofol doses for adjacent patients were set to be equidistantly spaced up and down by 0.05 mg/kg. Evaluation of the eyelash reflex and speech reflex was performed after intravenous infusion of ciprofol to observe whether LOC occurred within 4 min. After loss of consciousness, sufentanil (5ug/ml, diluted in 0.9% saline) and rocuronium bromide were given for endotracheal intubation.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Elderly Patients

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SEQUENTIAL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Intervention Type DRUG

The initial dose of ciprofol was 0.2mg/Kg for induction in this group.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ciprofol dose 0.4mg/Kg

The initial dose of ciprofol was 0.4mg/Kg for induction in this group.

Intervention Type DRUG

Ciprofol dose 0.3mg/Kg

The initial dose of ciprofol was 0.3mg/Kg for induction in this group.

Intervention Type DRUG

Ciprofol dose 0.2mg/Kg

The initial dose of ciprofol was 0.2mg/Kg for induction in this group.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

0.4mg/Kg ciprofol 0.3mg/Kg ciprofol 0.2mg/Kg ciprofol

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 65 ≤ age years;
* ASA physical state I and II;
* Hadn't a history of allergy to the drugs used in this study;

Exclusion Criteria

* America Society of Anesthesiologists (ASA) class \>III;
* Allergic to anesthetic solutions or the drugs used in this study;
* Body mass index (BMI) ≤ 20 or ≥ 30 kg/m2;
* Using hypnotics, opioid analgesics, or anti-anxiety medications;
* Known or suspected heart failure (ejection fraction \<40%), severe respiratory disease, renal or metabolic disease
* Refuse to participate or participate with other clinical investigators ;

Minimum Eligible Age

65 Years

Maximum Eligible Age

105 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No